There is news this week on a recent article titled: On the use of antiangiogenetic medications for retinopathy of prematurity.
From the article:
In contrast to the adult, the third trimester fetus experiences one of the most intense periods of growth and maturation of its lifetime. Early development is characterized by the existence of critical periods when environmental factors effectively produce long lasting changes.
Proliferative Retinopathy of Prematurity (ROP) is a potentially blinding disease characterized by uncontrolled retinal angiogenesis. This pathologic angiogenesis is the target for two new treatment modalities for retinopathy of prematurity (ROP) i.e. intravitreal anti VEGF (bevacizumab) and systemic propranolol, which are being evaluated in ongoing or planned studies. VEGF is essential for normal angiogenesis in a growing infant and the adrenergic system is important for many organ systems and, in addition, for plasticity of the visual and olfactory systems.
Conclusion: This viewpoint raises concerns regarding the currently studied antiangiogenetic treatments for ROP and their possible general effects on the developing preterm infant.
There may be some question that Avastin is a source of treatment instead of laser therapy to cure retinopathy of prematurity. It's important to discuss this medication to treat r.o.p.